← Back to Search

Procedure

Light Therapy for Autism (IPMR ASD Trial)

N/A
Recruiting
Research Sponsored by State University of New York - Upstate Medical University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

IPMR ASD Trial Summary

This trial will test if a light therapy device can help reduce symptoms of autism in children. #Autism #LightTherapy #ClinicalTrial

Who is the study for?
This trial is for children aged 2-8 who have been diagnosed with Autism Spectrum Disorder and have a CARS-2 score between 30 and 45, indicating a certain level of autism symptoms. Details on who cannot participate are not provided.Check my eligibility
What is being tested?
The study tests the effects of transcranial photobiomodulation (tPBM), which uses light treatment called Cognilum TM, on autistic children. It's randomized and double-blind, meaning neither participants nor researchers know who gets real or sham treatment.See study design
What are the potential side effects?
Specific side effects are not listed in the provided information. Generally, tPBM is considered non-invasive but may include discomfort or other reactions at the site of application.

IPMR ASD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Childhood Autism Rating Scale, Second edition
Secondary outcome measures
Clinical Global Impressions Scale
Social Responsiveness Scale, Second Edition

IPMR ASD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CognilumTMExperimental Treatment1 Intervention
During the study participants will be wear the transcranial photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.
Group II: Sham controlPlacebo Group1 Intervention
During the study participants will wear the transcranial photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognilum TM: Light Treatment Condition
2022
N/A
~60

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcranial Photobiomodulation (tPBM) is a treatment that uses light to stimulate cellular activity in the brain. This therapy involves the application of near-infrared light to the scalp, which penetrates the skull and reaches brain tissues. The light energy is absorbed by cellular mitochondria, leading to increased production of adenosine triphosphate (ATP), enhanced cellular metabolism, and reduced oxidative stress. These effects can improve neuronal function and connectivity, which are often impaired in Autism Spectrum Disorder (ASD). This matters for Autism patients as it offers a non-invasive method to potentially enhance brain function and alleviate some of the behavioral and cognitive symptoms associated with ASD.
Optogenetic Dissection of Neural Circuits Underlying Stress-Induced Mood Disorders.The Treatment of Sleep Dysfunction in Neurodegenerative Disorders.Social behavior in mice following chronic optogenetic stimulation of hippocampal engrams.

Find a Location

Who is running the clinical trial?

State University of New York - Upstate Medical UniversityLead Sponsor
173 Previous Clinical Trials
27,358 Total Patients Enrolled
JelikaLite LLCIndustry Sponsor
2 Previous Clinical Trials
56 Total Patients Enrolled
~9 spots leftby Aug 2024